Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer (NCT03925662) (2019)

Government Record · Sherief Abd-Elsalam, Tanta University (sponsor-investigator) · April 24, 2019

Sherief Abd-Elsalam et al., 2019-04-24: Registry record for a phase 3 Egyptian trial adding mebendazole to FOLFOX plus bevacizumab in colorectal cancer. The record lists 40 planned participants and a 2028 estimated completion; it has not posted results.

Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer

n/a

Sherief Abd-Elsalam et al., 2019-04-24: Registry record for a phase 3 Egyptian trial adding mebendazole to FOLFOX plus bevacizumab in colorectal cancer. The record lists 40 planned participants and a 2028 estimated completion; it has not posted results. Record field quoted from the official title; registry record. Study type: phase 3, randomized, active-comparator, open-label. N=40 estimated. Country: Egypt. Dose: not stated in the registry record; mebendazole added to FOLFOX plus Avastin. Sponsor: Sherief Abd-Elsalam, Tanta University. Status: RECRUITING; start 2019-04-01; estimated completion 2028-12. hasResults=false. Comparator: FOLFOX plus Avastin alone. No published results located; the record has not been updated since 2019. Registry entry; no results posted.